Our top pick for
Halozyme Therapeutics, Inc is a biotechnology business based in the US. Halozyme Therapeutics shares (HALO) are listed on the NASDAQ and all prices are listed in US Dollars. Halozyme Therapeutics employs 136 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$22.11 - $56.40|
|50-day moving average||$44.63|
|200-day moving average||$42.14|
|Wall St. target price||$49.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.91|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Halozyme Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Halozyme Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Halozyme Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 56x. In other words, Halozyme Therapeutics shares trade at around 56x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Halozyme Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $145.8 million.
The EBITDA is a measure of a Halozyme Therapeutics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$267.6 million|
|Operating margin TTM||53.91%|
|Gross profit TTM||$190 million|
|Return on assets TTM||15.74%|
|Return on equity TTM||106.33%|
|Market capitalisation||$7.3 billion|
TTM: trailing 12 months
There are currently 7.0 million Halozyme Therapeutics shares held short by investors – that's known as Halozyme Therapeutics's "short interest". This figure is 9.5% down from 7.8 million last month.
There are a few different ways that this level of interest in shorting Halozyme Therapeutics shares can be evaluated.
Halozyme Therapeutics's "short interest ratio" (SIR) is the quantity of Halozyme Therapeutics shares currently shorted divided by the average quantity of Halozyme Therapeutics shares traded daily (recently around 1.2 million). Halozyme Therapeutics's SIR currently stands at 6. In other words for every 100,000 Halozyme Therapeutics shares traded daily on the market, roughly 6000 shares are currently held short.
However Halozyme Therapeutics's short interest can also be evaluated against the total number of Halozyme Therapeutics shares, or, against the total number of tradable Halozyme Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Halozyme Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Halozyme Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.057% of the tradable shares (for every 100,000 tradable Halozyme Therapeutics shares, roughly 57 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Halozyme Therapeutics.
Find out more about how you can short Halozyme Therapeutics stock.
We're not expecting Halozyme Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Halozyme Therapeutics's shares have ranged in value from as little as $22.11 up to $56.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Halozyme Therapeutics's is 1.4137. This would suggest that Halozyme Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.